1. Timing of new black box warnings and withdrawals for prescription medications;Lasser;JAMA,2002
2. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) Guidance for Industry. E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs 2005
3. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Guidance for Industry. E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs - Questions and Answers (R1) 2012
4. Clinical pharmacokinetics and pharmacodynamics of ledipasvir/sofosbuvir, a fixed-dose combination tablet for the treatment of hepatitis C;German;Clin Pharmacokinet,2016
5. Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the Hepatitis C Virus NS5B polymerase inhibitor sofosbuvir;Kirby;Clin Pharmacokinet,2015